Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | MERTK | Q12866 | 8/20 | 0.32 |
| ▸ | AXL | P30530 | 5/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 5/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
| ▸ | CPB1 | P15086 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12067752 | 1.00 | CHRM3 (0.33) | CHRM3DRD2F2PRSS1HTR1A | |
| SCHEMBL19575551 | 0.87 | CHRM3 (0.34) | CHRM3MERTKAXLTYRO3 | |
| SCHEMBL12067807 | 0.87 | F2 (0.33) | CHRM3DRD2F2PRSS1HTR1A | |
| SCHEMBL14852948 | 0.87 | F2 (0.33) | CHRM3DRD2F2PRSS1HTR1A | |
| SCHEMBL10280031 | 0.86 | CHRM3 (0.33) | CHRM3 | |
| SCHEMBL12670478 | 0.82 | CHRM3 (0.36) | CHRM3 | |
| SCHEMBL14315896 | 0.80 | AKR1C3 (0.39) | CHRM3 | |
| SCHEMBL18362873 | 0.79 | VCP (0.40) | — | |
| SCHEMBL13409937 | 0.78 | OPRL1 (0.36) | OPRL1 | |
| SCHEMBL13635193 | 0.78 | CHRM3 (0.33) | CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
| EP-2397482-A1 | Heteroaryl imidazolone derivatives as jak inhibitors | Almirall, S.A. (ES) | 2011-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | CHRM3 4805/4885DRD2 3721/4885F2 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.